Analyst Weekly, November 3, 2025
Commerce Diplomacy: US’s “Asia Blitz” Targets China
Whereas D.C. argued over spending, the US administration was busy redrawing Asia’s commerce map. Offers had been completed with Malaysia, Cambodia, Vietnam, and Thailand, all carrying provisions designed to curb China’s affect, from banning items made with compelled labor to tightening export controls on delicate applied sciences.
On the similar time, Washington and Beijing reached a one-year “managed decoupling” truce: China paused new rare-earth export bans, the US delayed new sanctions on Chinese language companies, and either side agreed to extra agricultural and vitality commerce. The objective, no less than for now, is to sluggish the financial separation with out derailing international provide chains.
Investor Takeaway: Anticipate renewed momentum in “China-plus-one” commerce beneficiaries like Vietnam, Thailand, and India. ETFs monitoring rising Asian manufacturing might acquire from redirected provide chains. US semiconductor and vitality exporters additionally stand to profit as commerce flows rebalance.
Allies within the Fold: Japan, South Korea, and the AI Angle
The US additionally deepened its alliances with Japan and South Korea, putting funding pacts throughout nuclear vitality, shipbuilding, and synthetic intelligence (AI). Japan dedicated to assist finance $80 billion value of US nuclear tasks, whereas South Korea’s $350 billion funding plan, a long-debated bundle, will now prioritize heavy manufacturing and maritime industries.
In the meantime, tech cooperation took heart stage: Washington and Tokyo agreed to coordinate AI and quantum computing growth, making certain that allies depend on US-made AI chips. Taiwan additionally reported “progress” in its personal commerce talks, reinforcing America’s expertise sphere of affect.
Investor Takeaway: This “friendshoring” momentum is bullish for AI infrastructure and chipmakers tied to US provide chains. Names in semiconductors, clear vitality, and industrial robotics might see sustained demand. Lengthy-term buyers may take a look at international thematic funds targeted on AI or next-gen manufacturing.
Key Earnings Studies: Week of November 3, 2025
Palantir Applied sciences (PLTR): Traders will probably be laser-focused on the uptake of Palantir’s new Synthetic Intelligence Platform (AIP) and its function in accelerating the corporate’s progress. The increasing industrial use-cases for Palantir’s AI-driven analytics have analysts predicting a ~50% YoY income soar, underscoring the view that Palantir is on the forefront of the AI revolution.
Pfizer (PFE): Traders will probably be expecting steerage and new product momentum, searching for indicators that Pfizer’s non-COVID portfolio (which grew 14% within the prior 12 months’s quarter) can offset the steep decline in COVID franchise gross sales and restore earnings progress.
Superior Micro Units (AMD): Wall Road is concentrated on momentum in AMD’s increasing AI and cloud segments, anticipating ~27% YoY gross sales progress fueled by demand for EPYC server processors and new AI accelerators; a development buyers hope can maintain AMD’s 2025 rally intact within the face of PC market headwinds.
Uber Applied sciences (UBER): The highlight is on execution and margin self-discipline as Uber strives for sustainable profitability throughout rides and supply. Traders are expecting regular ride-hailing revenue margins and bettering unit economics in meals supply; stable bookings progress coupled with price management might lengthen Uber’s 2025 inventory surge, whereas any slip in effectivity or demand would elevate doubts about its post-pandemic revenue trajectory.
BP (BP): The main target will probably be on money circulation and strategic portfolio strikes amid an unsure oil worth outlook. Traders are eager for updates on BP’s plan to promote its Castrol lubricants unit, a divestment geared toward boosting shareholder worth, and can scrutinize how larger refining margins (anticipated to raise quarterly earnings) are balancing out softer upstream earnings.
Qualcomm (QCOM): Qualcomm’s report will check whether or not rising progress areas can overcome weak spot in its core smartphone chip enterprise. Traders will gauge if demand for Qualcomm’s AI-enabled chips and enlargement into PCs, autos, and IoT can offset continued softness in international handset gross sales, the smartphone market stays Qualcomm’s stronghold however has been sluggish, so any commentary on handset demand or diversification (e.g. wins in premium telephones or PC processors) will doubtless drive the inventory’s response.
Shopify (SHOP): The e-commerce platform’s valuation rests on balancing fast progress with bettering profitability. The important thing metric will probably be Shopify’s gross merchandise quantity (GMV) and income progress (guided within the high-20% vary) relative to its expense self-discipline, buyers wish to see continued 20%+ GMV enlargement alongside proof that current price cuts are boosting margins and free money circulation, which might validate Shopify’s post-rally valuation.
McDonald’s (MCD): The fast-food big’s same-store gross sales combine is the vital focus this quarter. Traders are watching how profitable McDonald’s new worth meal promotions have been in driving buyer visitors versus their influence on common examine dimension; early analyst insights counsel the September launch of Additional Worth Meals doubtless lifted foot visitors however dented common ticket, so the corporate’s comparable gross sales (anticipated ~+2.5% YoY) and administration’s commentary on pricing will set the post-earnings tone.
Novo Nordisk (NVO): The Danish pharma heavyweight’s outcomes will hinge on its blockbuster weight problems and diabetes medicine. Ozempic and Wegovy now account for roughly 65% of Novo Nordisk’s gross sales, so buyers will probably be laser-focused on the quarterly income from these GLP-1 medicines. Any replace on demand vs. provide constraints for Wegovy, and Novo’s capacity to maintain excessive progress within the face of latest opponents, will probably be pivotal in driving the inventory’s response.
Moderna (MRNA): Moderna’s narrative is shifting from COVID windfall to pipeline promise. With COVID-19 vaccine income sharply down, the important thing for buyers is any signal of stabilization in booster demand and progress in Moderna’s non-COVID pipeline. Specifically, updates on the uptake of its new fall COVID booster and the standing of upcoming vaccines (like RSV or flu) are essential – the market desires reassurance that Moderna’s subsequent era of merchandise can fill the hole as COVID gross sales fade.
AstraZeneca (AZN): As a UK-based pharma big reporting this week, AstraZeneca’s core oncology and uncommon illness drug gross sales would be the focus. Traders are significantly tuned to progress traits for key most cancers therapies and the corporate’s outlook amid upcoming drug patent expirations. Any updates on its pipeline (particularly in areas like oncology and the burgeoning diabetes/weight problems market) and the way it navigates drug pricing pressures within the US and Europe will doubtless drive AstraZeneca’s shares following earnings.
Airbnb (ABNB): The house-sharing platform’s quarter will activate the power of journey demand and reserving traits. The metric to observe is nights booked and common every day charges, as Airbnb has been posting round 8 to 10% income progress. Traders will probably be listening to administration’s commentary on reserving momentum into the vacations and any alerts of client journey urge for food or margin strain – it will decide if Airbnb can keep its post-pandemic progress trajectory and excessive profitability into 2026.
Amgen (AMGN): As a newly inducted Dow part, Amgen’s story is about new medicine changing previous ones. The main target is on whether or not Amgen’s lineup of newer therapies and its Horizon Pharma acquisition are producing sufficient progress to offset patent fades and biosimilar competitors on growing old blockbusters. Traders will parse Amgen’s earnings and steerage for proof that its revolutionary medicine (and value cuts) are driving income positive aspects, a key issue behind Amgen’s market-beating efficiency this 12 months, as it will decide if the inventory’s outperformance can proceed.
Market Pulse: Vol, Skew, and a GLD Hangover
Regardless of political noise, the S&P 500 traded sideways by the heaviest stretch of earnings. Volatility cooled as earnings rolled on, with the VIX slipping beneath mid-October highs. Large Tech earnings had been combined: Meta and Microsoft slipped, whereas Google held up. A big gold name place that had pushed months of upside was lower, signaling that the steel’s 2025 rally might have peaked.
Volatility stays inverted, with near-term choice costs larger than long-term ones; a setup that often normalizes as earnings cross.
Investor Takeaway: With short-term volatility easing, broader fairness participation might resume, suppose mid-caps and worth shares. As gold cools, funds might rotate into equities or bonds. Traders searching for diversification may rebalance out of valuable metals and into dividend ETFs or high quality cyclical names.
Palantir: Robust Rally, Excessive Expectations Forward of Q3 Earnings
Palantir Applied sciences is ready to report its Q3 earnings after the shut on Monday. The corporate, which focuses on information analytics and software program platforms, now ranks among the many 20 most respected companies within the S&P 500. The inventory has surged greater than 160% this 12 months.
The market is presently in a brand new upward impulse, with the long-term uptrend confirmed by a recent file excessive final week. Within the short-term the inventory seems barely overbought, because the RSI sits above 70. With a ahead P/E above 260, the elemental valuation may be very excessive, growing the chance of a correction. Even minor disappointments might set off vital volatility.
Analysts count on Palantir’s income to have risen 50.5% year-over-year to $1.09 billion within the third quarter, whereas earnings per share are projected to have grown by 67.4% over the identical interval. Ought to the inventory come below strain within the coming days or perhaps weeks, there are two key assist zones (Honest Worth Gaps) to observe:
$171.26 to $172.84 – a zone examined thrice already, with patrons defending it every time.
$160.87 to $161.06 – a deeper assist space that might come into focus if a correction unfolds.
Palantir, weekly chart. Supply: eToro
Novo Nordisk: Can Q3 Outcomes Forestall Additional Losses?
Novo Nordisk will report its third-quarter outcomes on Wednesday earlier than the European market opens. The inventory has been in a downtrend for over a 12 months and has misplaced round 70% of its worth for the reason that file excessive in July 2024.
In July and August, the share worth reacted to a long-term assist zone (Honest Worth Hole) between 290 and 310 DKK, which dates again to the 2021 rally. Nonetheless, this response alone wasn’t sufficient to set off a sustained development reversal. Though there was a short-term rebound, solely a break above resistance at 463 DKK would considerably enhance the technical image.
The upcoming earnings report will doubtless be decisive, exhibiting whether or not Novo Nordisk will proceed its downward trajectory or if the long-term assist space provides an opportunity for a backside formation.
Analysts count on income within the third quarter to have risen 7.9% year-on-year to 76.9 billion DKK, whereas earnings per share are projected to fall 19.1% to 4.95 DKK.
Novo Nordisk, weekly chart. Supply: eToro
This communication is for data and training functions solely and shouldn’t be taken as funding recommendation, a private suggestion, or a suggestion of, or solicitation to purchase or promote, any monetary devices. This materials has been ready with out bearing in mind any specific recipient’s funding targets or monetary scenario and has not been ready in accordance with the authorized and regulatory necessities to advertise impartial analysis. Any references to previous or future efficiency of a monetary instrument, index or a packaged funding product aren’t, and shouldn’t be taken as, a dependable indicator of future outcomes. eToro makes no illustration and assumes no legal responsibility as to the accuracy or completeness of the content material of this publication.
